Novacyt S.A. Executive Management and Proposed Board Changes (5190K)
January 05 2021 - 1:00AM
UK Regulatory
TIDMNCYT
RNS Number : 5190K
Novacyt S.A.
05 January 2021
Novacyt S.A.
("Novacyt" or the "Company" or the "Group" )
Executive Management and Proposed Board Changes
Paris, France and Camberley, UK - 5 January 2021 - Novacyt (
EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in
clinical diagnostics, announces that James McCarthy has been
appointed as Chief Financial Officer (CFO), whilst Anthony Dyer has
taken on a new role as Chief Corporate Development Officer (CCDO).
Both appointments are with immediate effect.
Mr McCarthy will become a Board Director of the Company, subject
to shareholder approval, at the AGM. Anthony Dyer will remain a
Board Director until James McCarthy is elected to the Board.
James has held a number of senior positions in major listed and
private equity-backed businesses. Most recently he was CFO of Flint
Group, a $2.5bn revenue, PE backed business with 7,900 staff and
180 sites across 40 countries. Previously, he was CFO of Brambles
Plc's EMEA CHEP business before being promoted to President of
CHEP's European team. Brambles Plc is an Australian-based, ASX
listed business with a market capitalisation of AU$16bn. James
trained as an accountant with Dairygold, receiving his ACCA
qualification in 1988, before going on to work for a range of
businesses including Unilever and ICI Plc.
Graham Mullis, Chief Executive Officer of Novacyt, commented
:
"On behalf of the Board, I am pleased to welcome James to the
role of CFO. He joins Novacyt having held senior finance positions
at a number of large blue-chip manufacturing organisations. His
considerable financial, commercial and Board experience will be
invaluable as Novacyt embarks on its next stage of growth.
"I would also like to take this opportunity to thank Anthony
personally for the key role he has played in helping transform
Novacyt into a leading diagnostics developer and manufacturer. His
new, important role reflects the Company's growth strategy, which
includes selective potential M&A to supplement organic growth
initiatives. I look forward to working with Anthony and James as
part of an expanded executive team."
The information required by Rule 17 and paragraph (g) of
Schedule 2 of the AIM Rules for Companies in relation to the
appointment of James Martin McCarthy (age 54) is as follows:
Current directorships Past directorships held within
last five years
Energy Transition Forum Limited CHEP Israel Limited
Focus4Value Limited Xeikon NV.
XBC BV
Mr McCarthy holds 10,000 ordinary shares in the Company. There
are no other disclosures required in accordance with Schedule 2(g)
of the AIM Rules.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Steve Gibson, Group Finance Director
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
alex.shaw@fticonsulting.com / mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAPFLESAFEFA
(END) Dow Jones Newswires
January 05, 2021 02:00 ET (07:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2023 to Apr 2024